This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.
Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.

 

This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.

Are you a healthcare professional?
Lisbon
2024
Symposium

Date and time:

12.05.24 at 12:30-13:30 WEST

Type:

Congress:
Speakers:

Opening and welcome

Phenotyping HFpEF: Concept or clinical practice?

Expert discussion: What does the HFpEF patient journey entail?

What’s next in HFpEF?

Panel discussion and Q&A

properties.alt

Anique Ducharme

University of Montreal, Montreal, Canada


Dr Anique Ducharme is a Professor of Medicine and chair holder of the University of Montreal’s, Montreal, QC, Canada, Fondation Marcelle et Jean Coutu and Cal and Janine Moisan for best practices in advanced heart failure. She is the founder and director of the Heart Failure Clinic at the Montreal Heart Institute (MHI), Montreal, QC, and a past president of the Canadian Heart Failure Society. She was the recent scientific programme committee chair for the Canadian Cardiovascular Society (CCS) annual congress (2018 to 2020) where she implemented mandatory 3G politics to promote diversity in terms of gender, geography and generation, and led the pivot from an in-person to a fully virtual meeting. She has also been involved in the CCS Heart Failure Guidelines Committee since 2006. She is the programme director for the University of Montreal Advanced Heart Failure and Cardiac Transplantation fellowship programme and the current co-chair of the International Society of Heart and Lung Transplantation (ISHLT) on the evaluation of transplant candidates.

 

She is an associate director of the Canadian Heart Function Alliance, a national research network that was recently funded by the Canadian Institutes of Health Research (CIHR). She has published over 165 peer-reviewed articles including in the New England Journal of Medicine, Lancet and Circulation, 16 book chapters, 200 abstracts and 2 online university tutorial courses, and is currently on or has served on several steering committees for large-scale studies, including HERMES, GUIDE-HF, SYMPHONY, STICH, AF-CHF, EARTH, RELAX-HF and CHARM. She is an associate editor for the International Journal of Cardiology: Heart and Vasculature and also participates in several review panels for journals, including Circulation, Journal of the American College of Cardiology, Journal of Cardiac Failure, Canadian Medical Association Journal and Canadian Journal of Cardiology.

 

Dr Ducharme graduated from Université de Montréal, Montreal, QC, in 1991 in medicine (MD) and biomedical sciences (MSc, Cardiac Transplantation) and completed her residency in cardiology in 1996. She pursued additional training in echocardiography at the MHI, then in Molecular Biology and Heart Failure at the Brigham and Women’s Hospital, Harvard Medical School in Boston, MA, USA. Since her return in 1999, she has held a position in the non-invasive cardiology department at the MHI, where she carries out activities in echocardiography, advanced heart failure and cardiac transplantation. Her clinical and research focus is on advanced heart failure, including remodelling, pharmacological and device therapies (cardiac resynchronisation therapy, percutaneous valvular interventions, pulmonary pressure monitoring, mechanical assist devices and transplantation).


Read full bio
properties.alt

Mikhail Kosiborod

Saint Luke’s Health System, Kansas, USA


Dr Mikhail Kosiborod is a Cardiologist and Vice President of Research at Saint Luke’s Health System, Kansas City, MO, USA. He is also an executive director of the Cardiometabolic Center Alliance, Kansas City, MO, a director of Cardiometabolic Research and co-director of the Haverty Cardiometabolic Center of Excellence at Saint Luke’s Mid America Heart Institute, Kansas City, MO. He is a Professor of Medicine at the University of Missouri-Kansas City School of Medicine, Kansas City, MO, and the inaugural recipient of the Ben McCallister, MD Endowed Chair in Cardiovascular Research at Saint Luke’s Health System. 

 

Dr Kosiborod is an internationally recognised expert in the field of cardiometabolic disease and has authored and co-authored more than 400 peer-reviewed publications. Dr Kosiborod has conducted and been involved in the leadership of numerous national and international clinical trials, including DEFINE-HF, DAPA-HF, DELIVER, DARE-19, EMBRACE-HF, EMPULSE, PRESERVED-HF, REALIZE-K and STEP-HFpEF, many of which have had a significant impact on treatment guidelines and clinical practice. Dr Kosiborod’s body of work has been central to the elucidation of the impact of sodium-glucose co-transporter-2 inhibition and GLP-1 receptor agonism in improving cardiovascular outcomes and survival in various clinical settings, perhaps some of the most important advances in clinical cardiology seen in a generation.


Read full bio